The President opened the meeting at 12.00 and welcomed all attendees.

1. Minutes of the Annual General Meeting held on 16 September 2016

The minutes were approved as presented.

2. Report and audited accounts for year ended 31 December 2016

The accounts were approved as presented.
3. Presentations from:

**The President**

The President did not give a formal presentation as he had presented a detailed overview of his term as President during the IHC Opening Ceremony.

**The Treasurer**

The final figures for 2016 were presented to the Board in May. The accounts have now been audited and presented in statutory format and approved by the Board. The statutory accounts are publicly available on the UK Companies House and UK Charity Commission websites.

- 2016 income: £ 544,261
- 2016 expenditure: £ 438,069
- Surplus: £ 106,192

**Income:**

- Membership: £ 103,582 – 19% of income, membership fees stable
- Cephalalgia royalty: £ 218,991 – 40% of income, good level of reprints and institutional sales, main annual source of income
- Donations/sponsorship: £ 192,719 – 36% of income, includes £ 125,000 sponsorship for an iHEAD and a fellowship and £ 67,000 from the Corporate Roundtable
- Investment income: £ 28,969 – 5% of income

**Expenditure:**

- Education: £ 95,439 – 22% of expenditure, almost £ 72,000 on iHEAD
- Fellowships/grants: £ 86,140 – 20% of expenditure, includes £ 50,000 fellowship, £ 21,500 EHMTIC travel grants, £ 13,500 short-stay scholarships
- Committee costs: £ 73,827 – 17% of expenditure, includes ARCH, South Korea, £ 24,000
- Cost of Cephalalgia: £ 52,947 – 12% of expenditure
- Support costs: £ 129,411 – 29% of expenditure

The overall income increases in alternate years with the income from the congress.

Membership fees remain stable; over the years the membership options have changed with a decrease in members choosing the print journal option and moving to online-only, as expected.

IHS has shown a surplus over the past 2 years and there will be a surplus in 2017. Reserves are healthy with over £ 1.5 million. As a registered charity reserves need to be kept at a level that is neither too high or too low – usually aiming for 2.5-years operating costs. In years when there is a deficit these reserves maintain the society and its activities. By the end of 2017 reserves may be as high as £ 1.8 million, and the IHS Board will discuss the best way to use this surplus.
The Secretary

In 2017 IHS welcomed Kyrgyzstan as the 50th Affiliate Member Society – it is excellent news that countries from Asia are joining IHS.

Membership numbers in 2017 have increased; there are now 1391 members compared with 1277 in 2016 – the highest member numbers seen since 2003. There were 168 new members (the same as in 2016) who joined directly with IHS – other new members joined through the Affiliate Societies.

It is always a concern that members do not renew and in 2017 there were 268. However, it was encouraging that in 2016 the number was 349 – in 2017 the President personally emailed non-renewed members to invite them to rejoin.

The membership fee has remained stable since 2011 and the Board agreed in the recent Board meeting that there would be no increase for 2018.

The number of Associate Members, membership offered free of charge to researchers and physicians from developing countries, increased to 950.

There are three membership categories: Standard, Junior and Adjunct/Corporate. Adjunct/Corporate membership is offered to people working for industry and lay people interested in headache. IHS always has an increased number of members in IHC years as people join to attend the congress. The number of junior members has also risen; many juniors join on recommendation of their department heads, and also to apply for IHS grants.

Maurice Vincent left Board in Feb 2017 as he moved to an industry position.

Elections for the Board of Trustees was held and there was a 42.1% turnout, the highest seen.

Cephalalgia has had a good year financially. The Impact Factor has decreased but this was not unexpected – the 2015 impact factor was high as the ICHD-3-beta citations were included, but were not in 2016. The journal is ranked 45 of 179 in clinical neurology journals, and 79/258 in neuroscience journals.

After long negotiations with the publisher the contract for the new open-access title, Cephalalgia Reports, has been signed. The journal will be fully open access and aims to publish case reports, reviews, and educational publications. IHS and the publisher will begin publicising the journal and the Editor is encouraging all IHS members to submit their papers.

IHS continues to be active in Education.

IHS supported the 2nd MENA (Middle East and North Africa) meeting in Morocco. The 3rd MENA will probably be held in Egypt in 2018. This is a new region for headache education and research and IHS is pleased to be able to support activities there.
Visiting Professors were sent to Russia and Iran and a Headache Trainee was awarded to study in London, starting later in September.

The 4th European iHEAD was held in October 2016 in London, and an IHA in the US in January 2017. Immediately prior to the IHC a joint iHEAD/IHA was held in Vancouver and this brought many young people to the congress.

In 2018 a Master School is planned for Australia.

The Trainees and Residents SIG awarded three short-stay scholarships and 30 travel grants for IHC. Two IHS Fellowships were awarded in 2017.

Funding from the Corporate Roundtable membership enables funding of IHS education activities and grants.

The collaboration between IHS and IASP is continuing and it is hoped to have a joint session during every IHS and IASP congress

The final version of the ICHD-3 is almost complete and will publish in Cephalalgia in 2018. The ICD-11 is in preparation.

IHS is collaborating with LTB on a small global burden paediatric study in Zambia – the first one in this country. It is hoped this will be the first of a series undertaken in three or four countries – there are a number of countries interested.

The next congress will be held in Dublin, Ireland, in September 2019 under the title 'Dawn of new headache treatments'. MCI is appointed as the congress organiser.

IHC 2021 will be held in Helsinki, Finland. Negotiations with the venue are ongoing.

The recent IHS Global Patient Advocacy Summit held in Vancouver prior to IHC brought together for the first time key stakeholders to discuss patient advocacy in headache medicine.

4. Re-appointment of the auditors

The recommendation to re-appoint MacIntyre Hudson LLP to audit the 2017 accounts was approved.

5. Appointment of the Board of Trustees

The following members have been selected by the members through an online or postal ballot to join the Board of Trustees:

President-elect: Messoud Ashina
Elected Trustees: Mario Peres
Patricia Pozo-Rosich
Todd Schwedt

The election of the members was unanimously approved.

Initial .........
The following members will be automatically re-elected to serve a second term on the Board of Trustees:

Anna Ambrosini
Rigmor Jensen
Gisela Terwindt

6. Election of Honorary Members

The election of Dr Alan Rapoport as an Honorary Member was unanimously approved.

7. Date of next meeting

The next AGM will be held on 7 September 2018 in London, UK.

The meeting was adjourned at 12:30.